+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hemophilia Drug"

From
Human Factor VIII Concentrate Market - Global Forecast 2026-2032 - Product Thumbnail Image

Human Factor VIII Concentrate Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 199 Pages
  • Global
From
Emicizumab Injection Market - Global Forecast 2026-2032 - Product Thumbnail Image

Emicizumab Injection Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 193 Pages
  • Global
From
Bleeding Disorder Drugs - Global Strategic Business Report - Product Thumbnail Image

Bleeding Disorder Drugs - Global Strategic Business Report

  • Report
  • November 2026
  • 488 Pages
  • Global
From
From
From
From
From
From
From
From
Coagulation Factor Deficiency Market Report 2026 - Product Thumbnail Image

Coagulation Factor Deficiency Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
From
From
From
From
From
From
Loading Indicator

The Hemophilia Drug market is a subset of the larger Hematological Drugs market. Hemophilia drugs are used to treat and prevent bleeding episodes in people with hemophilia, a rare genetic disorder. These drugs are typically administered intravenously or subcutaneously and are designed to replace the missing clotting factor in the patient's blood. Commonly used hemophilia drugs include recombinant factor VIII and IX, as well as plasma-derived factor VIII and IX. The Hemophilia Drug market is highly competitive, with a number of companies offering a variety of products. Some of the major players in the market include Pfizer, Novo Nordisk, Bayer, Biogen, CSL Behring, and Shire. Show Less Read more